

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

---

### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Moxifloxacin Solid Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd  
Macquarie Park NSW, Australia 2113

Telephone : +1-908-740-4000

Emergency telephone number : 1 800 033 461

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification


Acute toxicity (Oral) : Category 4

Serious eye damage/eye irritation : Category 2B

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure : Category 2 (Liver)

#### GHS label elements

Hazard pictograms : 

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.  
H320 Causes eye irritation.  
H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs (Liver) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

## Moxifloxacin Solid Formulation

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
 Date of first issue: 05.06.2017

P264 Wash skin thoroughly after handling.  
 P270 Do not eat, drink or smoke when using this product.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 40 -<= 70
Cellulose	9004-34-6	>= 10 -<= 30

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention.

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

---

- |   |   |   |
|---|---|---|
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.             |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed.<br>Causes eye irritation.<br>Suspected of damaging the unborn child.<br>May cause damage to organs through prolonged or repeated exposure.            |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician  | : | Treat symptomatically and supportively.   |
- 

### SECTION 5. FIREFIGHTING MEASURES

- |   |   |   |
|---|---|---|
| Suitable extinguishing media                  | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                | : | None known.   |
| Specific hazards during fire-fighting         | : | Exposure to combustion products may be a hazard to health.  |
| Hazardous combustion products                 | : | Carbon oxides   |
| Specific extinguishing methods                | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- |   |   |   |
|---|---|---|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).  |
| Environmental precautions   | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Retain and dispose of contaminated wash water.<br>Local authorities should be advised if significant spillages cannot be contained.   |
| Methods and materials for containment and cleaning up               | : | Sweep up or vacuum up spillage and collect in suitable container for disposal.<br>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.<br>Sections 13 and 15 of this SDS provide information regarding |

## Moxifloxacin Solid Formulation

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
 Date of first issue: 05.06.2017

certain local or national requirements.

## SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust, fume, gas, mist, vapours or spray.  
 Do not swallow.  
 Do not get in eyes.  
 Avoid prolonged or repeated contact with skin.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	AU OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

## Moxifloxacin Solid Formulation

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
 Date of first issue: 05.06.2017

**Personal protective equipment**

- || Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- || Filter type : Particulates type
- Hand protection : Chemical-resistant gloves
- Material : Chemical-resistant gloves
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- || Skin and body protection : Work uniform or laboratory coat.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- Appearance : solid
- Colour : pink
- Odour : odourless
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available
- Flammability (solid, gas) : Not classified as a flammability hazard
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapour pressure : No data available
- Relative vapour density : No data available
- || Relative density : No data available
- Density : No data available

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

---

Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	Not applicable
Particle size	:	No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	:	Skin contact Ingestion Eye contact
-----------------	---	--

#### Acute toxicity

|| Harmful if swallowed.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: 1,886 mg/kg Method: Calculation method
---------------------	---	--

#### Components:

#### Moxifloxacin HCL:

Acute oral toxicity	:	LD50 (Rat): 1,320 mg/kg LD50 (Mouse): > 435 mg/kg LD50 (Monkey): 1,500 mg/kg
---------------------	---	--

**Moxifloxacin Solid Formulation**

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
Date of first issue: 05.06.2017

---

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes eye irritation.

**Components:****Moxifloxacin HCL:**

Species : Rabbit  
Result : Moderate eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: positive  
  
Test Type: Chromosome aberration test in vitro  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
  
Test Type: in vitro micronucleus test  
Result: negative

## Moxifloxacin Solid Formulation

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
 Date of first issue: 05.06.2017

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Application Route: Oral  
 Result: negative

**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: In vitro mammalian cell gene mutation test  
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks  
 Result : negative

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Oral  
 Fertility: LOAEL: 500 mg/kg body weight  
 Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Monkey  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 10 mg/kg body weight  
 Result: negative

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Intravenous injection  
 Developmental Toxicity: LOAEL: 20 mg/kg body weight  
 Symptoms: Skeletal malformations



## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs (Liver) through prolonged or repeated exposure.

### Components:

#### Moxifloxacin HCL:

Target Organs : Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Moxifloxacin HCL:

Species : Rat  
LOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 4 Weeks

Species : Rat  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Liver  
Symptoms : Liver disorders

Species : Rat  
NOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Liver  
Symptoms : Liver disorders

Species : Monkey  
NOAEL : 50 mg/kg  
Application Route : Oral

**Moxifloxacin Solid Formulation**

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
Date of first issue: 05.06.2017

---

Exposure time : 4 Weeks  
Symptoms : No adverse effects

Species : Monkey  
NOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Gastrointestinal tract  
Symptoms : Vomiting

Species : Monkey  
Application Route : Oral  
Exposure time : 26 Weeks  
Target Organs : Liver  
Symptoms : Liver disorders

**Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Moxifloxacin HCL:**

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)):  $> 100$  mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Bioaccumulative potential**

No data available

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

---

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

- |                        |   |  |
|------------------------|---|--|
| Waste from residues    | : | Dispose of in accordance with local regulations.   |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. |
|                        |   | If not otherwise specified: Dispose of as unused product.                                      |
- 

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable

#### IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

#### IMDG-Code

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

UN number	:	Not applicable
Proper shipping name	:	Not applicable

**Moxifloxacin Solid Formulation**

Version 2.0      Revision Date: 13.10.2021      SDS Number: 1731671-00007      Date of last issue: 13.09.2019  
Date of first issue: 05.06.2017

---

Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Hazchem Code : Not applicable

**Special precautions for user**

Not applicable

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

**SECTION 16. OTHER INFORMATION****Further information**

Revision Date : 13.10.2021  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average  
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.0	13.10.2021	1731671-00007	Date of first issue: 05.06.2017

---

Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN